SCHEMBL23462293

SCHEMBL23462293

O=c1c(Cl)c(N2CCC(O)C2)cnn1C1CCCCO1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 2/20 0.38
▸ LMNA P02545 1/20 0.38
▸ POLB P06746 1/20 0.38
▸ RAB9A P51151 2/20 0.35
▸ GAA P10253 1/20 0.35
▸ CYP4F2 P78329 2/20 0.34
▸ CYP4A11 Q02928 2/20 0.34
▸ RXRA P19793 1/20 0.34
▸ RXRB P28702 1/20 0.34
▸ RXRG P48443 1/20 0.34
▸ IRAK4 Q9NWZ3 1/20 0.33
▸ KMT2A Q03164 2/20 0.33
▸ SMN1; SMN2 Q16637 2/20 0.33
▸ MEN1 O00255 1/20 0.33
▸ NPC1 O15118 1/20 0.33
▸ CHEK1 O14757 1/20 0.32
▸ CNR2 P34972 1/20 0.32
▸ ATR Q13535 1/20 0.32
▸ OPRM1 P35372 2/20 0.32
▸ OPRD1 P41143 2/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23462292 1.00 ALDH1A1 (0.38) ALDH1A1LMNAPOLBRAB9AGAA
SCHEMBL20818486 0.93 ALDH1A1 (0.40) ALDH1A1LMNAPOLBRAB9AGAA
SCHEMBL23933193 0.86 LMNA (0.38) ALDH1A1LMNAPOLBRAB9ACYP4F2
SCHEMBL23933195 0.86 LMNA (0.38) ALDH1A1LMNAPOLBRAB9ACYP4F2
SCHEMBL30268685 0.86 RAB9A (0.44) ALDH1A1LMNAPOLBRAB9AGAA
SCHEMBL23462309 0.84 ALDH1A1 (0.36) ALDH1A1LMNAPOLBCYP4F2CYP4A11
SCHEMBL23462308 0.84 ALDH1A1 (0.36) ALDH1A1LMNAPOLBCYP4F2CYP4A11
SCHEMBL20818806 0.82 ALDH1A1 (0.40) ALDH1A1LMNAPOLBRAB9AGAA
SCHEMBL20817906 0.82 ALDH1A1 (0.40) ALDH1A1LMNAPOLBRAB9AGAA
SCHEMBL23462437 0.82 ALDH1A1 (0.37) ALDH1A1LMNAPOLBRAB9AGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12509444-B2 Compounds and methods for CD73 modulation and indications therefor PLEXXIKON INC. (US) 2025-12-30 — — US disclosed
US-12202818-B2 Compounds and methods for CD73 modulation and indications therefor Opna Bio SA (CH) 2025-01-21 — — US disclosed
EP-4139296-B1 COMPOUNDS AND METHODS FOR CD73 MODULATION AND INDICATIONS THEREFOR Opna Bio SA (CH) 2024-09-18 — — EP disclosed
US-20240174640-A1 COMPOUNDS AND METHODS FOR CD73 MODULATION AND INDICATIONS THEREFOR Opna Bio SA (CH) 2024-05-30 — — US disclosed
US-11807626-B2 Compounds and methods for CD73 modulation and indications therefor Opna Bio SA (CH) 2023-11-07 — — US disclosed
CN-116323588-A Compounds and methods for CD73 modulation and indications therefor 奥普纳生物有限公司 2023-06-23 — — CN disclosed
EP-4139296-A1 COMPOUNDS AND METHODS FOR CD73 MODULATION AND INDICATIONS THEREFOR Opna Immuno Oncology, SA (CH) 2023-03-01 — — EP disclosed
US-20220144805-A1 COMPOUNDS AND METHODS FOR CD73 MODULATION AND INDICATIONS THEREFOR Opna Bio SA (CH) 2022-05-12 — — US disclosed
WO-2021216898-A1 COMPOUNDS AND METHODS FOR CD73 MODULATION AND INDICATIONS THEREFOR PLEXXIKON INC. (US) 2021-10-28 — — WO disclosed
US-20210198239-A1 COMPOUNDS AND METHODS FOR CD73 MODULATION AND INDICATIONS THEREFOR PLEXXIKON INC. 2021-07-01 — — US disclosed
WO-2021113625-A1 COMPOUNDS AND METHODS FOR CD73 MODULATION AND INDICATIONS THEREFOR PLEXXIKON INC. (US) 2021-06-10 — — WO disclosed
WO-2021113625-A1 COMPOUNDS AND METHODS FOR CD73 MODULATION AND INDICATIONS THEREFOR PLEXXIKON INC. (US) 2021-06-10 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12202818-B2 Compounds and methods for CD73 modulation and indications therefor ENTPD5, ENTPD1, ADORA2A ALDH1A1 208/4885LMNA 1207/4885POLB 1748/4885
US-20240174640-A1 COMPOUNDS AND METHODS FOR CD73 MODULATION AND INDICATIONS THEREFOR ENTPD5, ENTPD1, ADORA2A ALDH1A1 208/4885LMNA 1207/4885POLB 1748/4885
US-20210198239-A1 COMPOUNDS AND METHODS FOR CD73 MODULATION AND INDICATIONS THEREFOR ENTPD5, ADORA2A, ENTPD1 ALDH1A1 216/4885LMNA 1383/4885POLB 1763/4885
US-12509444-B2 Compounds and methods for CD73 modulation and indications therefor ENTPD5, ADORA1, ADORA2A ALDH1A1 114/4885LMNA 1484/4885POLB 2540/4885
US-11807626-B2 Compounds and methods for CD73 modulation and indications therefor ENTPD5, ENTPD1, ADORA2A ALDH1A1 208/4885LMNA 1207/4885POLB 1748/4885
US-20220144805-A1 COMPOUNDS AND METHODS FOR CD73 MODULATION AND INDICATIONS THEREFOR ENTPD5, ENTPD1, ADORA2A ALDH1A1 208/4885LMNA 1218/4885POLB 1741/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback